文献速递心境障碍

加速dTMS治疗重性抑郁障碍:18-Hz rTMS与iTBS的疗效、安全性及EEG功能连接比较

Comparison of the clinical efficacy, safety and EEG functional connectivity changes between 18-Hz rTMS and iTBS of accelerated dTMS treatment for major depressive disorder: a randomized controlled trial.
PubMed 文献 · Mol Psychiatry · 2026-05-11

一项随机对照试验(n=73)比较加速dTMS的18-Hz rTMS方案、iTBS方案与单用药物治疗重性抑郁障碍的疗效。两种dTMS方案均每日两次、持续10天,HAMD评分均显著下降,应答率和缓解率均高于单用药物;iTBS-dTMS疗效与18-Hz rTMS-dTMS相当,且两者诱导不同频段的功能连接改变。

要点

  • 加速dTMS的iTBS方案与18-Hz rTMS方案均显著降低HAMD评分,疗效优于单用药物。
  • iTBS-dTMS组应答率85.7%、缓解率50.0%,rTMS-dTMS组分别为76.9%和42.3%,均高于药物组。
  • 两种方案诱导不同频段功能连接改变:rTMS-dTMS主要减弱alpha频段,iTBS-dTMS主要减弱theta频段。

核心结论

  • 加速dTMS的iTBS方案在疗效和耐受性上与18-Hz rTMS方案相当,均优于单用药物治疗重性抑郁障碍。
  • 两种加速dTMS方案诱导治疗特异性的网络水平神经生理改变,支持iTBS-dTMS作为高效循证治疗选择。

研究设计与样本

  • 随机对照试验,共纳入73例重性抑郁障碍患者。
  • 分为三组:18-Hz rTMS加速dTMS组、iTBS加速dTMS组和单用药物组。
  • 两种dTMS方案均每日两次、持续10天,靶点为左侧前额叶外侧皮层(包括背外侧区域)。

主要发现

  • iTBS-dTMS组HAMD评分从治疗前22.5±3.7降至治疗后8.2±4.1(t=15.900,p<0.001)。
  • rTMS-dTMS组HAMD评分从治疗前21.3±2.9降至治疗后8.0±3.8(t=17.232,p<0.001)。
  • 药物组HAMD评分从24.7±6.8降至14.0±5.0(t=6.363,p<0.001)。
  • iTBS-dTMS组应答率85.7%、rTMS-dTMS组76.9%,均高于药物组42.1%;缓解率分别为50.0%、42.3%,均高于药物组10.5%。
  • 静息态EEG显示rTMS-dTMS组主要减弱alpha频段额-枕、额-颞、额-中央网络功能连接,iTBS-dTMS组主要减弱theta频段额-顶、额-枕、额-颞通路功能连接。

关键数值与推荐

  • iTBS-dTMS组HAMD评分治疗前后分别为22.5±3.7和8.2±4.1(t=15.900,p<0.001)。
  • rTMS-dTMS组HAMD评分治疗前后分别为21.3±2.9和8.0±3.8(t=17.232,p<0.001)。
  • 药物组HAMD评分治疗前后分别为24.7±6.8和14.0±5.0(t=6.363,p<0.001)。
  • 应答率:iTBS-dTMS组85.7%,rTMS-dTMS组76.9%,药物组42.1%;缓解率:iTBS-dTMS组50.0%,rTMS-dTMS组42.3%,药物组10.5%。

临床怎么用

  • 加速dTMS的iTBS方案可作为重性抑郁障碍的高效治疗选择,疗效与18-Hz rTMS方案相当且耐受性良好。
  • 两种方案均每日两次、10天短疗程,可能有助于提高治疗容量和患者依从性。
  • rTMS-dTMS组额-颞/中央区功能连接相对变化与HAMD减分率呈显著负相关,iTBS-dTMS组额-顶区功能连接相对变化与HAMD减分率呈显著正相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Although the antidepressant efficacy of 18-Hz deep transcranial magnetic stimulation (dTMS) has been validated, its prolonged treatment duration has considerable limitations for treatment capacity and patient adherence. Therefore, novel short-course protocols such as accelerated dTMS and intermittent theta burst stimulation (iTBS) present promising alternative options. Here we addressed the question of whether iTBS of accelerated dTMS achieves comparable therapeutic and electrophysiological effects to accelerated dTMS with the conventional 18-Hz rTMS protocol in patients with major depressive disorder (MDD). In a randomized controlled trial (n = 73), participants received either 18-Hz rTMS of accelerated dTMS (rTMS-dTMS group), iTBS of accelerated dTMS (iTBS-dTMS group), or pharmacotherapy alone (drug group). Both dTMS protocols were administered twice daily for 10 days targeting the left lateral prefrontal cortex including the dorsolateral region. Results showed that Hamilton Depression Rating Scale (HAMD) score of the iTBS-dTMS group decreased significantly from 22.5 ± 3.7 before treatment to 8.2 ± 4.1 after treatment (t = 15.900, p < 0.001). HAMD score of the rTMS-dTMS group decreased significantly from 21.3 ± 2.9 before treatment to 8.0 ± 3.8 after treatment (t = 17.232, p < 0.001). The drug group also exhibited significantly improved patients' mood symptoms, and the HAMD score decreased from 24.7 ± 6.8 to 14.0 ± 5.0 (t = 6.363, p < 0.001). The treatment response rate was 85.7% in the iTBS-dTMS group and 76.9% in the rTMS-dTMS group, which was much higher than that of the drug group (42.1%). The remission rate was 50.0% in the iTBS-dTMS group and 42.3% in the rTMS-dTMS group, which was significantly higher than 10.5% of the drug group. We demonstrate here that both accelerated dTMS protocols significantly reduced HAMD scores, improved the response rates, and remission rates, outperforming pharmacotherapy alone. Resting-state EEG analysis further revealed unique frequency-specific functional connectivity (FC) modulation effects: the rTMS-dTMS group primarily exhibited weakened alpha-band functional connectivity within the fronto-occipital, fronto-temporal and fronto-central networks after treatment, whereas the iTBS-dTMS group predominantly demonstrated reduced theta-band functional connectivity within the fronto-parietal, fronto-occipital and fronto-temporal pathways after treatment. These findings indicate that iTBS of accelerated dTMS demonstrates comparable efficacy and tolerability to 18-Hz rTMS of accelerated dTMS, whilst inducing treatment-specific network-level neurophysiological alterations. In the rTMS-dTMS group, relative changes in FC between the frontal and temporal/precentral regions showed significant negative correlation with HAMD score reduction rates, while relative changes in FC between the frontal lobe and parietal lobe showed a significant positive correlation with the rate of HAMD score reduction for the iTBS-dTMS group. This study revealed novel mechanisms by which accelerated dTMS protocols modulate brain networks, providing evidence for the clinical application of accelerated iTBS-dTMS as an efficient, evidence-based treatment for MDD.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Yang L, Dai H, Zhu M, et al. Comparison of the clinical efficacy, safety and EEG functional connectivity changes between 18-Hz rTMS and iTBS of accelerated dTMS treatment for major depressive disorder: a randomized controlled trial. Mol Psychiatry. 2026. PMID: 42115366. doi:10.1038/s41380-026-03633-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。